drugset
Drugs / TQB2825
last change May 2026 re-read 2 minutes ago

TQB2825

also known as TQB2825 injection
Developed for
diffuse large B-cell lymphoma · B-cell neoplasm · follicular lymphoma · hematopoietic and lymphoid cell neoplasm
Investigated by
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Trials 5 · a red edge is where a trial was stopped

today NCT07187960 · Ph 3 NCT07110194 · Ph 1 NCT06829771 · Ph 1/2 NCT06854445 · Ph 2 NCT05489276 · Ph 1
202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07110194 Sep 2025 → Mar 2026 overdue B-cell neoplasm Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT05489276 Mar 2022 → Oct 2023 hematopoietic and lymphoid cell neoplasm Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT06829771 Apr 2025 → May 2026 overdue diffuse large B-cell lymphoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06854445 Mar → Oct 2025 overdue diffuse large B-cell lymphoma Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07187960 Nov 2025 → Oct 2028 expected follicular lymphoma Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as TQB2825 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07187960 ↗
4

NCT05489276 ↗

NCT06829771 ↗

NCT06854445 ↗

NCT07110194 ↗
Known as TQB2825 injection “TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2.” NCT05489276 ↗
Action Deplete “thereby killing CD20 positive tumor cells” NCT05489276 ↗
Route Intravenous “TQB2825 injection is given intravenously every 2 weeks” NCT05489276 ↗